A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata

Treatment of alopecia areata in pre‐adolescent children with oral tofacitinib: A retrospective study

(2020) Rebekka Jerjen et al.   PEDIATRIC DERMATOLOGY

JAK inhibitors and alopecia areata

(2019) Amos Gilhar et al.   LANCET

JAK inhibitors for alopecia areata: a systematic review and meta-analysis

(2019) Kevin Phan et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta‐analysis

(2019) Linghong Guo et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Experience with oral tofacitinib in two adolescents and seven adults with alopecia areata

(2019) Neslihan Akdogan et al.   Dermatologic Therapy

Ruxolitinib cream for the treatment of patients with alopecia areata: A 2-part, double-blind, randomized, vehicle-controlled phase 2 study

(2019) Elise A. Olsen et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Emerging Topical and Systemic JAK Inhibitors in Dermatology

(2019) Farzan Solimani et al.   Frontiers in Immunology

A Case Report Highlighting the Effective Treatment of Alopecia Universalis With Tofacitinib in an Adolescent and Adult Patient

(2018) Nupur U. Patel et al.   JOURNAL OF CUTANEOUS MEDICINE AND SURGERY

An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis

(2018) A. Jabbari et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Alopecia areata is a medical disease

(2018) Dorota Z. Korta et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients

(2018) Lucy Y. Liu et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Carcinogenicity assessment of baricitinib in Tg.rasH2 mice and Sprague-Dawley (Crl:CD) rats

(2018) Mark Carfagna et al.   REGULATORY TOXICOLOGY AND PHARMACOLOGY

JAK Inhibitors for Treatment of Alopecia Areata

(2018) Eddy H.C. Wang et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Ruxolitinib for the treatment of severe alopecia areata

(2018) Lucy Y. Liu et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

OUP accepted manuscript

(2018)   RHEUMATOLOGY

Role of janus kinase inhibitors in the treatment of alopecia areata

(2018) Korn Triyangkulsri et al.   Drug Design Development and Therapy

Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring

(2017) Amy Vandiver et al.   INTERNATIONAL JOURNAL OF DERMATOLOGY

A Case of Topical Ruxolitinib Treatment Failure in Alopecia Areata

(2017) Maya Deeb et al.   JOURNAL OF CUTANEOUS MEDICINE AND SURGERY

Oral tofacitinib monotherapy in Korean patients with refractory moderate-to-severe alopecia areata: A case series

(2017) Hyun-Sun Park et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Experience with oral tofacitinib in 8 adolescent patients with alopecia universalis

(2017) Leslie Castelo-Soccio   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients

(2017) Lucy Y. Liu et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Tofacitinib for the treatment of alopecia areata and variants in adolescents

(2017) Brittany G. Craiglow et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata

(2017) Cheryl B. Bayart et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

JAK inhibitors in dermatology: The promise of a new drug class

(2017) William Damsky et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Successful hair regrowth in a Korean patient with alopecia universalis following tofacitinib treatment

(2017) BY Kim et al.   SINGAPORE MEDICAL JOURNAL

Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers

(2016) Ali Jabbari et al.   EXPERIMENTAL DERMATOLOGY

Functional Interpretation of Genome-Wide Association Study Evidence in Alopecia Areata

(2016) Lynn Petukhova et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)

(2016) John E. Harris et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Treatment of recalcitrant adult alopecia areata universalis with oral azathioprine

(2016) Sergio Vañó-Galván et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy of tofacitinib in treatment of alopecia universalis in two patients

(2016) A.K. Gupta et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

The role of lymphocytes in the development and treatment of alopecia areata

(2015) Hongwei Guo et al.   Expert Review of Clinical Immunology

Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation

(2015) Eleanor Higgins et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci

(2015) Regina C. Betz et al.   Nature Communications

Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib

(2015) Ali Jabbari et al.   EBioMedicine

Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia

(2014) Lisa Pieri et al.   AMERICAN JOURNAL OF HEMATOLOGY

Efficacy and safety of methotrexate in alopecia areata

(2014) Mariana Hammerschmidt et al.   ANAIS BRASILEIROS DE DERMATOLOGIA

Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis

(2014) Brittany G. Craiglow et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition

(2014) Luzhou Xing et al.   NATURE MEDICINE

Therapeutic Targeting of the JAK/STAT Pathway

(2013) Saara Aittomäki et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease

(2012) John J. O'Shea et al.   IMMUNITY

The Pharmacokinetics, Pharmacodynamics, and Safety of Orally Dosed INCB018424 Phosphate in Healthy Volunteers

(2011) Jack G. Shi et al.   JOURNAL OF CLINICAL PHARMACOLOGY